Private Equity

With a new M&A-savvy CRO and Blackstone's backing, Enverus is poised for aggressive growth, aiming to dominate the AI-driven future of energy intelligence.

As a £2.3B buyout of JTC plc looms, a hedge fund's growing bet via derivatives reveals the complex power plays governed by UK takeover transparency rules.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

A routine dividend from Imperial Petroleum reveals a powerful strategy: a debt-free balance sheet and cash-funded growth in a volatile shipping market.

A routine regulatory filing reveals First Trust's 4.99% stake in NCC Group, fueling speculation around the struggling cybersecurity firm's future.

A 1.26% stake in Just Group, held via derivatives by Balyasny, reveals a classic merger arbitrage strategy as Brookfield's £2.4bn acquisition nears.

A key advisory appointment reveals a pivotal trend in private equity: a move from deal-making to deep operational focus for maximizing portfolio returns.

Trinity Consultants' acquisition of CEQA/NEPA expert Meridian is more than a regional deal; it's a strategic move with deep implications for biopharma.

J.P. Morgan's 2026 outlook reveals how private markets, fueled by AI, are rebuilding the physical backbone of the global supply chain.

A former oil driller pivots to advanced recycling, but can its plastics-to-fuel plant navigate financial risks and environmental scrutiny in Texas?

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

A $104M loan for a Lynbrook luxury tower reveals a major shift in real estate finance and highlights soaring demand for transit-oriented living.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

The waterpark giant is investing millions to trade slides for serenity. We analyze Kalahari's strategic leap into the booming luxury experience market.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

How a social media-fueled cosmetics brand leveraged its whimsical aesthetic to land a major deal with Ulta, rewriting the playbook for digital-first success.

A mandatory disclosure from a Boston investment giant reveals its position in a $1.4B merger. What does it signal for the future of the auto industry?

A new grant funds maternal health navigators in Mississippi, building a human infrastructure to combat one of the nation's worst maternal health crises.

Amidst a nuclear renaissance, Global Uranium’s detailed mapping in Wyoming de-risks a key project, setting the stage for a critical 2026 drill program.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.